Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) EPS (Basic) (2016 - 2025)

Lineage Cell Therapeutics' EPS (Basic) history spans 16 years, with the latest figure at -$0.15 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 1397.68% year-over-year to -$0.15; the TTM value through Dec 2025 reached -$0.28, down 180.0%, while the annual FY2025 figure was -$0.28, 211.11% down from the prior year.
  • EPS (Basic) reached -$0.15 in Q4 2025 per LCTX's latest filing, down from -$0.13 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.01 in Q4 2024 to a low of -$0.17 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$0.05, with a median of -$0.04 recorded in 2022.
  • The largest YoY upside for EPS (Basic) was 83.33% in 2021 against a maximum downside of 1800.0% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at -$0.17 in 2021, then surged by 82.35% to -$0.03 in 2022, then changed by 0.0% to -$0.03 in 2023, then skyrocketed by 66.67% to -$0.01 in 2024, then plummeted by 1397.68% to -$0.15 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's EPS (Basic) are -$0.15 (Q4 2025), -$0.13 (Q3 2025), and -$0.13 (Q2 2025).